AstraZeneca pours more money into the Moderna pot

AstraZeneca ($AZN) has added an extra $140 million into the much-hyped early-stage mRNA biotech Moderna Therapeutics, adding to the company’s already huge VC cash pile of more than $1.2 billion.

This is according to Reuters, which said the two had extended their deal this week. Neither Astra nor Moderna however have released this publicly, and did not respond to requests from FierceBiotech about the upped stake.

The cash boost news comes just a few weeks after Moderna announced it would start the first trial under its existing collab with AstraZeneca. The Phase I study will test their experimental cardiometabolic drug AZD8601.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The biotech’s core tech is focused on using messenger RNA, or mRNA, to spur the production of human proteins within patient cells, creating what Moderna describes as an in vivo factory for targeted therapies.

AstraZeneca first signed up to a research pact with the biotech--a Fierce 15 company--back in 2013, and at the start of the year also saw the two pen another pact, this time on immuno-oncology mRNA therapeutics.

AstraZeneca is not the only one interested; Moderna has also gained much attention and R&D deals from Alexion ($ALXN), Merck ($MRK) and Vertex ($VRTX).

Reuters said that the new investment, part of a preferred-stock financing, lifted Astra’s stake in Moderna to 9%, up from its original investment three years ago.

- check out the Reuters story

Special Report: Moderna Therapeutics - 2013 Fierce 15

Related Articles:
Cash-rich Moderna to begin first AstraZeneca trial under collab deal
Much-hyped Moderna barrels into the clinic with 6 human trials planned for '16

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.